A
5.15
0.01 (0.19%)
| 前收盘价格 | 5.14 |
| 收盘价格 | 5.10 |
| 成交量 | 561,755 |
| 平均成交量 (3个月) | 311,440 |
| 市值 | 224,506,528 |
| 价格/销量 (P/S) | 37.76 |
| 股市价格/股市净资产 (P/B) | 5.91 |
| 52周波幅 | |
| 利润日期 | 13 May 2025 - 19 May 2025 |
| 稀释每股收益 (EPS TTM) | -1.55 |
| 总债务/股东权益 (D/E MRQ) | 52.35% |
| 流动比率 (MRQ) | 6.08 |
| 营业现金流 (OCF TTM) | -56.02 M |
| 杠杆自由现金流 (LFCF TTM) | -37.88 M |
| 资产报酬率 (ROA TTM) | -46.41% |
| 股东权益报酬率 (ROE TTM) | -216.57% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Abeona Therapeutics Inc. | 看涨 | 看跌 |
AIStockmoo 评分
0.8
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.0 |
| 平均 | 0.75 |
|
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 6.59% |
| 机构持股比例 | 68.18% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 20.00 (HC Wainwright & Co., 288.35%) | 购买 |
| 中 | 18.00 (249.52%) | |
| 低 | 16.00 (Oppenheimer, 210.68%) | 购买 |
| 平均值 | 18.00 (249.52%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 5.30 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Apr 2025 | 20.00 (288.35%) | 购买 | 5.33 |
| 24 Mar 2025 | 15.00 (191.26%) | 购买 | 5.12 | |
| Oppenheimer | 05 Mar 2025 | 16.00 (210.68%) | 购买 | 5.26 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合